全球微脂体阿霉素市场：市场规模、份额、成长分析 - 按产品、按应用、产业预测（2024-2031）

Global Liposomal Doxorubicin Market Size, Share, Growth Analysis, By Product(J7J (Doxil/Caelyx), Sun Pharma (Lipodox)), By Application(leukemia, bone sarcoma) - Industry Forecast 2024-2031

出版日期: 2024年03月10日 | 出版商:

SkyQuest | 英文 219 Pages | 商品交期: 3-5个工作天内

价格

简介目录

全球微脂体阿霉素市场规模将于2022年达到12.7亿美元，2023年达到13.5亿美元，2024-2031年预测期间复合年增长率为6.1%，预计将成长至21.6亿美元。

微脂体阿霉素市场正在显着成长，这主要是由于肉瘤盛行率的上升。微脂体体阿霉素用于治疗多种恶性，包括乳癌、卵巢癌和卡波西氏肉瘤。这是一种封装在微脂体中的抗癌化疗药物，脂质体是封闭的脂质球。有几个因素促进了这个全球市场的成长，包括医疗保健设施的进步、医疗成本的成长趋势、患者对潜在治疗方法的认识提高以及基本药物学名药的普及。然而，由于学名药竞争加剧以及FDA对新药认证的严格要求，市场拓展可能面临挑战。此外，由于人们对替代药物的认识不断提高，以及公共和私营部门主要製造商的重大投资，预计该市场将实现盈利的开拓。由于先前对卵巢癌和与爱滋病相关的卡波西氏肉瘤的全身治疗不足，微脂体阿霉素的销售量预计将显着增加。此外，肝细胞癌的发生率和存活率不断上升，进一步推动了对微脂体阿霉素的需求。

Johnson & Johnson
Sun Pharmaceutical Industries Ltd.
Pfizer Inc.
Teva Pharmaceutical Industries Ltd.
Celsion Corporation
Gilead Sciences, Inc.
Eisai Co., Ltd.
Ligand Pharmaceuticals
Sandoz（a division of Novartis）
Eagle Pharmaceuticals, Inc.
Dr. Reddy's Laboratories Ltd.
Pacira BioSciences, Inc.
Formosa Laboratories, Inc.
Intas Pharmaceuticals Ltd.
Zydus Cadila
TTY Biopharm
Luye Pharma Group Ltd.
CP Pharmaceuticals Ltd.
Actavis（now part of Teva）
Ipsen SA

简介目录

Product Code: SQMIG35I2216

Global Liposomal Doxorubicin Market size was valued at USD 1.27 billion in 2022 and is poised to grow from USD 1.35 billion in 2023 to USD 2.16 billion by 2031, growing at a CAGR of 6.1 % in the forecast period (2024- 2031).

The market for liposomal doxorubicin is experiencing notable growth, primarily driven by the escalating prevalence of sarcoma. Liposomal doxorubicin is utilized in the treatment of various malignant tumors, including breast cancer, ovarian cancer, Kaposi sarcoma, among others. It is an anti-cancer chemotherapy medication enclosed within liposomes, which are closed lipid spheres. Several factors contribute to the growth of this global market, including advancements in healthcare facilities, the upward trajectory of healthcare expenses, heightened patient awareness regarding potential therapies, and the proliferation of generic versions of essential medications. However, the market expansion may face challenges due to intensifying competition from generic medications and stringent FDA requirements for the approval of new drugs. Moreover, the market is poised to witness profitable development due to the increasing awareness of alternative medications and substantial investments made by key manufacturers in both public and private sectors. The sales of liposomal doxorubicin are anticipated to witness a significant upsurge owing to the inadequacy of prior systemic treatments for ovarian cancer and Kaposi's sarcoma associated with AIDS. Additionally, the incidence and survival rates of hepatocellular carcinoma are on the rise, further fueling the demand for liposomal doxorubicin.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Liposomal Doxorubicin Market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Liposomal Doxorubicin Market Segmental Analysis

The Global Liposomal Doxorubicin Market is segmented on the basis of product, application, and region. By Product, the market is segmented into J7J (Doxil/Caelyx), Sun Pharma (Lipodox), and Teva (Myocet). By Applicatopn, the market is segmented into leukemia, bone sarcoma, breast cancer, gastric cancer, liver cancer, kidney cancer, multiple myeloma, ovarian cancer, Kaposi sarcoma, and others. By region, the market is segmented into North America, Latin America, Europe, Asia Pacific, and MEA.

Drivers of the Global Liposomal Doxorubicin Market

Liposomal doxorubicin is predominantly employed in the treatment of breast cancer, a disease that is witnessing a concerning surge in many countries. The growing innovation in formulations stands out as a key factor driving the increased adoption and usage of the drug for breast cancer treatment. These advancements contribute significantly to the expansion of the market. Moreover, several other factors are expected to further propel the market in the forthcoming years. These include the escalating demand for pharmaceuticals utilized in targeted therapy, the heightened utilization of chemotherapy treatments, and substantial investments by private enterprises in this particular application. Government support for the healthcare sector also emerges as a critical element in expanding the global reach of the market.

Restraints in the Global Liposomal Doxorubicin Market

Anticipated adverse effects of liposomal doxorubicin may potentially impede market expansion. These effects include an elevated risk of infection, dyspnea, pale complexion, bruises, nosebleeds, pre- and post-treatment weakness, red, painful, and peeling hands and feet, weight loss, diarrhea, and fatigue.

Market Trends of the Global Liposomal Doxorubicin Market

Breast cancer stands out as the most prevalent cancer treated with doxorubicin, although this medication is also employed in the treatment of various other malignancies. According to a report by the International Agency for Research on Cancer (IARC) in December 2020, approximately 1 in 4 cancer diagnoses in women worldwide are cases of breast cancer. As per a World Health Organization article dated April 2021, there were 2.3 million women diagnosed with breast cancer in 2020, resulting in 685,000 fatalities globally. Projections indicate that by 2020, a staggering 7.8 million women will have received a breast cancer diagnosis, solidifying its status as the most commonly diagnosed cancer globally. Additionally, according to the American Cancer Institute, doxorubicin is a chemotherapy medication prescribed for the treatment of advanced breast cancer.

Executive Summary

Market Overview
Wheel of Fortune

Research Methodology

Information Procurement
Secondary & Primary Data Sources
Market Size Estimation
Market Assumptions & Limitations

Parent Market Analysis

Market Overview
Market Size
Market Dynamics
- Drivers
- Opportunities
- Restraints
- Challenges

Key Market Insights

Technology Analysis
Pricing Analysis
Supply Chain Analysis
Value Chain Analysis
Ecosystem of the Market
IP Analysis
Trade Analysis
Startup Analysis
Raw Material Analysis
Innovation Matrix
Pipeline Product Analysis
Macroeconomic Indicators
Top Investment Analysis
Key Success Factor
Degree of Competition

Market Dynamics & Outlook

Market Dynamics
- Drivers
- Opportunities
- Restraints
- Challenges
Regulatory Landscape
Porters Analysis
- Competitive rivalry
- Threat of Substitute Products
- Bargaining Power of Buyers
- Threat of New Entrants
- Bargaining Power of Suppliers
Skyquest Special Insights on Future Disruptions
- Political Impact
- Economic Impact
- Social Impact
- Technical Impact
- Environmental Impact
- Legal Impact

Global Liposomal Doxorubicin Market by Product

Market Overview
J7J (Doxil/Caelyx)
Sun Pharma (Lipodox)
and Teva (Myocet)

Global Liposomal Doxorubicin Market by Application

Market Overview
leukemia
bone sarcoma
breast cancer
gastric cancer
liver cancer
kidney cancer
multiple myeloma
ovarian cancer
Kaposi sarcoma
and others

Global Liposomal Doxorubicin Market Size by Region

Market Overview
North America
- USA
- Canada
Europe
- Germany
- Spain
- France
- UK
- Rest of Europe
Asia Pacific
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
Latin America
- Brazil
- Rest of Latin America
Middle East & Africa (MEA)
- GCC Countries
- South Africa
- Rest of MEA

Competitive Landscape

Top 5 Player Comparison
Market Positioning of Key Players, 2021
Strategies Adopted by Key Market Players
Top Winning Strategies
- By Development
- By Company
- By Year
Recent Activities in the Market
Key Companies Market Share (%), 2021

Key Company Profiles

Johnson & Johnson
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Sun Pharmaceutical Industries Ltd.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Pfizer Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Teva Pharmaceutical Industries Ltd.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Celsion Corporation
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Gilead Sciences, Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Eisai Co., Ltd.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Ligand Pharmaceuticals
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Sandoz (a division of Novartis)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Eagle Pharmaceuticals, Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Dr. Reddy's Laboratories Ltd.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Pacira BioSciences, Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Formosa Laboratories, Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Intas Pharmaceuticals Ltd.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Zydus Cadila
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
TTY Biopharm
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Luye Pharma Group Ltd.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
CP Pharmaceuticals Ltd.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Actavis (now part of Teva)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Ipsen S.A.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments